Osborne Clarke brings together a wealth of expertise across the full spectrum of domestic and international corporate, commercial, and M&A mandates. David Haex co-heads the team and leads on complex and cross-border M&A and venture capital transactions. Fellow co-lead Stefan Deswert is notable for his commercial law expertise, particularly in the real estate and distribution segments. Hadrien Chef offers a breadth of knowhow across restructuring, M&A, equity transactions, and early-stage financing rounds.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Osborne Clarke was with us every step of the way and their knowledge and aid during this negotiation was important to achieve the result we have today.'
- 'Quality listening partners, good feedback, willing to advise, quick response times, and overall very good communication.'
- ‘What truly sets this team apart is its responsiveness, and ability to operate as a true thought partner in complex cross-border matters.'
- 'The firm has demonstrated a rare ability to combine top-tier technical knowledge with a pragmatic, solutions-oriented approach—especially valuable in fast-paced, high-stakes environments.'
- 'In general, we’ve found the team to be highly collaborative, intellectually rigorous, and deeply invested in building long-term client relationships—not just handling transactions. That makes all the difference.’
- ‘Hadrien Chef proved to be an outstanding lawyer. He combines an incredibly sharp mind with relentless dedication — he was always available to drive the deal forward and keep everyone aligned.'
Key clients
- ActivPayroll
- Adecco Group
- ADEC Innovations
- Aidoptation
- Allcargo Logistics
- BioSenic
- Circular Innovation Fund
- Fortino Capital
- Founders of ATB Therapeutics
- HSBC
- Kester Capital
- KiOmed Pharma
Work highlights
Advised HSBC on its strategic Investment in TechWolf, a leading provider of AI-driven talent management solutions based in Belgium.
Advised the founders of ATB Therapeutics in securing €54m in an equity round co-led by EQT Life Sciences and MRL Ventures Fund, alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and other investors.
Assisted KiOmed Pharma, a leading biomedical company based in Liège, in their recent €18m fundraising.
Practice head
David Haex; Stefan Deswert
Other key lawyers
Hadrien Chef
